Company Announcement no. 14/2011
To: NASDAQ OMX Copenhagen A/S Hørsholm, Denmark, November 30, 2011
Articles of Association
Hørsholm, 30. November 2011 – Veloxis Pharmaceuticals A/S (OMX: VELO), have today registered new articles of association with the company register.
The new articles of association is attached.
For more information
| John D. Weinberg | Johnny Stilou |
| SVP, Commercial Operations and Investor Relations | CFO |
| Mobil: +1 908 304 3389 | Mobil: +45 2055 3852 |
| Email: jdw@veloxis.com | Email: st@veloxis.com |
About Veloxis Pharmaceuticals
Based in Hørsholm, Denmark, with an office in New Jersey, Veloxis Pharmaceuticals A/S, or Veloxis, is a specialty pharmaceutical company. Clinical development is the core of Veloxis’ efforts to develop a product portfolio which includes the Company’s lead product candidate, LCP‐Tacro™, for immunosuppression, specifically organ transplantation, and products to combat certain cardiovascular diseases. Veloxis adapts new technologies on a fast commercial timetable. Veloxis’ unique, patented delivery technology, MeltDose®, can improve absorption and bioavailability ‐ at low‐scale up costs ‐ not only for a broad spectrum of drugs already on the market but also for new chemical entities. Veloxis has a lipid lowering product, Fenoglide®, currently on the U.S. market and a diversified near and medium term pipeline with three clinical stage product candidates and a number of projects in preclinical development. Veloxis is listed on the NASDAQ OMX Copenhagen under the trading symbol OMX: VELO.
For further information, please visit www.veloxis.com.
